DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorPeking Union Medical College Hospital
About this trial
This study aims to compare the mid- and long-term outcomes between paclitaxel-coated balloon and primary selective stenting in the treatment of TASC C/D femoropopliteal artery occlusive disease.
Eligibility criteria
Qualifiers
Subject age 18-85yrs.
Subject has been informed of the nature of the study, agrees to participate, and has signed a Medical Ethics Committee approved consent form.
Subject understands the duration of the study, agrees to attend follow-up visits, and agrees to complete the required testing.
Rutherford category 2-5.
Disqualifiers
Acute thrombus in the target vessels.
Vessel stenosis or occlusion due to Buerger's disease or autoimmune arteritis.
Subject received prior stents implantation with in-stent restenosis or occlusion.
Reintervention of the target lesion <90 days before the study procedure.
Trial design
Treatments tested in this trial
- paclitaxel-coated balloon angioplasty or bare mental stents implantation
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov